A new study provides the first insights into epigenetic heterogeneity in AML. The study highlights a striking independence of genetic and epigenetic variation, and links the kinetics of epigenetic change to clinical outcome.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Greaves, M. Cancer Discov. 5, 806–820 (2015).
Ley, T.J. et al. N. Engl. J. Med. 368, 2059–2074 (2013).
Gawad, C., Koh, W. & Quake, S.R. Nat. Rev. Genet. 17, 175–188 (2016).
Marusyk, A., Almendro, V. & Polyak, K. Nat. Rev. Cancer 12, 323–334 (2012).
Grimwade, D., Ivey, A. & Huntly, B.J.P. Blood 127, 29–41 (2016).
Figueroa, M.E. et al. Cancer Cell 17, 13–27 (2010).
Li, S. et al. Nat. Med. 22, 792–799 (2016).
Li, S. et al. Genome Biol. 15, 472 (2014).
Pan, H. et al. Nat. Commun. 6, 6921 (2015).
Mazor, T. et al. Cancer Cell 28, 307–317 (2015).
The authors declare no competing financial interests.
About this article
Cite this article
Sasca, D., Huntly, B. Independence of epigenetic and genetic diversity in AML. Nat Med 22, 708–709 (2016). https://doi.org/10.1038/nm.4136